Obesity-Drug Success Allows Lilly CEO to Avoid Expensive Deals

Eli Lilly & Co. isn’t planning to make big acquisitions despite a monthslong buying spree across the biopharma industry.

Instead, Chief Executive Officer Dave Ricks said Lilly’s “sweet spot” is early-stage deals that will give the drugmaker access to new technology to make cutting-edge medicines.